PYPD
PolyPid Ltd.NASDAQHealthcare$4.39-3.42%ClosedMarket Cap: $44.7M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
7.96
P/S
0.00
EV/EBITDA
-1.22
DCF Value
$0.12
FCF Yield
0.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-291.4%
ROA
-153.2%
ROIC
-95.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-8.5M | $-0.41 |
| FY 2025 | $0.00 | $-34.2M | $-2.09 |
| Q3 2025 | $0.00 | $-7.5M | $-0.37 |
| Q2 2025 | $0.00 | $-10.0M | $-0.78 |
Analyst Ratings
View AllHC Wainwright & Co.Buy
2026-02-11Roth CapitalBuy
2025-11-13Craig-HallumBuy
2025-08-14HC Wainwright & Co.Buy
2025-08-13Roth CapitalBuy
2025-06-18Trading Activity
Insider Trades
View AllStein Robert Benjamindirector
SellMon Apr 06
Stein Robert Benjamindirector
SellMon Apr 06
Stein Robert Benjamindirector
SellMon Apr 06
Jacobovitz Yitzchak Shlomodirector:
SellMon Apr 06
Warshavsky Oriofficer: Chief Operating Officer - US
SellThu Mar 26
Company Info
Sector
Healthcare
Industry
—
Country
IL
Exchange
NASDAQ
Beta
1.46
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.